Hyundai Bioscience Co., Ltd.

Hyundai Bioscience is a biotechnology company dedicated to developing innovative antiviral and anticancer therapeutics by leveraging cutting-edge drug delivery systems (DDS). Our proprietary nanohybrid DDS technologies enhance the bioavailability of active pharmaceutical ingredients (APIs) and improve targeted drug delivery, maximizing therapeutic efficacy while minimizing adverse effects. Our Core Technologies & Products 🔹 XAFTY® – A broad-spectrum oral antiviral drug candidate based on niclosamide, targeting COVID-19, Long COVID, Dengue, Influenza, RSV, Mpox, Adenovirus, and other infectious diseases. 🔹 POLYTAXEL® – A pain-free anticancer treatment, utilizing a nanoparticle-based DDS to enhance the bioavailability and therapeutic effects of docetaxel, reducing toxicity and side effects while improving tumor selectivity. 🔹 PENETRIUM™ (CP-PCA07) – Approved for Phase 1 clinical trials in South Korea for castration-resistant prostate cancer (CRPC). PENETRIUM™ aims to address non-genetic resistance (pseudo-resistance) in combination with existing therapies, offering new potential solutions for resistant cancer types. 🔹 OTX-M™ – An oral metronomic chemotherapy using docetaxel, designed to sustain anticancer effects, minimize toxicity, and improve patient quality of life by enabling long-term, low-dose treatment strategies. What We Offer ✅ Innovative Drug Delivery Systems (DDS) – Enhancing drug solubility, stability, and targeted delivery through proprietary nanohybrid formulations. ✅ Broad-Spectrum Antiviral Therapeutics – Developing oral antiviral treatments to address global pandemic preparedness and neglected infectious diseases. ✅ Next-Generation Oncology Solutions – Advancing pain-free, targeted, and metronomic chemotherapy to improve cancer treatment efficacy and safety. With a strong commitment to scientific innovation and patient-centric therapies, Hyundai Bioscience is redefining the future of antiviral and oncology drug development.